$NTIC

Northern Technologies (NTIC) Earnings Transcript

This article provides an earnings transcript for Northern Technologies International Corporation (NTIC), highlighting recent positive financial performance. NTIC reported a Q2 Non-GAAP EPS of $0.01 and revenues of $21.99 million, a 15.3% year-over-year increase, driven by strong ZERUST® sales in industrial and oil & gas sectors, and expansion in China. Wall Street analysts maintain a "Moderate Buy" rating for NTIC, forecasting a stock price increase.

Original reporting
Intellectia AI · Emily J. Thompson
Published Apr 9, 2026, 4:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Apr 9, 2026, 5:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$NTIC
Bullish
high confidence
Mentioned
$NTIC
Relevance
6/10
AlphAI data visualization · based on Intellectia AI
Decision brief

The 30-second read

$NTICBullishMed
01

Why it matters

The earnings beat and sector expansion suggest a positive outlook, but valuation levels should be assessed to avoid overpaying.

02

Market read

The company's growth signals strength in niche industrial markets, with potential spillover effects in related sectors.

03

What to watch

Global economic slowdown or sector-specific headwinds could dampen growth prospects.

Relevance 6/10Timing: short to medium term (1-3 months)

Background

NTIC has been expanding its ZERUST® product line in industrial and oil & gas sectors, with recent success in China.

Company-level read

Ticker impact

$NTICBullishHigh confidence
Context

Primary focus of the news due to recent earnings report and positive outlook.

Expected impact

Moderate upward movement in stock price over the next 1-3 months.

Evidence & confidence

Strong quarterly results, sector growth, and analyst ratings support a bullish outlook. Limited negative factors observed.

Market effects

Positive sentiment for manufacturing and industrial sectors due to increased sales and expansion.

Potential positive impact on markets in North America and China where expansion occurred.

Moderate; primarily affects sectors and regions where NTIC operates.

Counterpoint

Potential overestimation of growth; earnings may be temporary or driven by one-time factors.

Key entities

  • NTIC

    Northern Technologies International Corporation, specializing in corrosion protection and sustainable solutions.

  • ZERUST®

    A corrosion prevention technology contributing significantly to revenue growth.

Related articles

$NTICMed

Why is Northern Technologies stock gaining today?

Northern Technologies (NTIC) stock rose 2.0% to $8.28 in pre-market trading following a leadership overhaul. Gautam Ramdas, an internal candidate, was named CEO, effective September 4, 2026, with the current CEO transitioning to Chairman. The broader market is down, but NTIC's move is driven by company-specific news. The company's recent quarterly results showed record sales but margin pressure. NTIC's stock is still below its 52-week high of $10.03.

$NTICMed

Northern Technologies International Corporation Reports Financial Results for Third Quarter Fiscal 2026

Northern Technologies International (NASDAQ: NTIC) reported third-quarter fiscal 2026 results. Consolidated net sales rose 12.6% to $24.216M, with ZERUST industrial up 10.3% and ZERUST oil and gas up 72.3%. Gross margin fell to 33.6% (down 477 bps). NTIC posted a $263k net loss ($0.03/share) versus net income a year earlier. The company cited higher raw material costs and pricing pressure.

$NTICMed

Northern Technologies International Corporation Reports Financial Results for Third Quarter Fiscal 2026

NORTHERN TECHNOLOGIES INTERNATIONAL CORP (NTIC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling EXHIBIT 99.1 Northern Technologies International Corporation Reports Financial Results for Third Quarter Fiscal 2026 MINNEAPOLIS, July 09, 2026 (GLOBE NEWSWIRE) -- Northern Technologies International Corporation (NASDAQ: NTIC), a le

$CLYMHighAI 8/10

Climb Bio reports early data on budoprutug for kidney diseases

Climb Bio (CLYM) presented Phase 2 trial data for budoprutug, an anti-CD19 antibody, showing B-cell depletion and PLA2R antibody reductions in kidney disease patients. The 200 mg dose achieved 70% mean antibody reduction, with 5/13 patients in remission. The 600 mg dose showed deeper B-cell depletion. The drug was well-tolerated. Climb Bio expects more data in 2027. Primary membranous nephropathy affects 75,000 people in the U.S. without FDA-approved treatments.